Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Laboratory of Molecular Pathology and NanoBioImaging, Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy.
Cancer Lett. 2024 Nov 28;605:217297. doi: 10.1016/j.canlet.2024.217297. Epub 2024 Oct 16.
Long non-coding RNAs (lncRNAs) have emerged as critical regulators of epigenome, modulating gene expression through DNA methylation, histone modification, and/or chromosome remodeling. Dysregulated lncRNAs act as oncogenes or tumor suppressors, driving tumor progression by shaping the cancer epigenome. By interacting with the writers, readers, and erasers of the epigenetic script, lncRNAs induce epigenetic modifications that bring about changes in cancer cell proliferation, apoptosis, epithelial-mesenchymal transition, migration, invasion, metastasis, cancer stemness and chemoresistance. This review analyzes and discusses the multifaceted role of lncRNAs in cancer pathobiology, from cancer genesis and progression through metastasis and therapy resistance. It also explores the therapeutic potential of targeting lncRNAs through innovative diagnostic, prognostic, and therapeutic strategies. Understanding the dynamic interplay between lncRNAs and epigenome is crucial for developing personalized therapeutic strategies, offering new avenues for precision cancer medicine.
长链非编码 RNA(lncRNA)已成为表观基因组的关键调控因子,通过 DNA 甲基化、组蛋白修饰和/或染色体重塑来调节基因表达。失调的 lncRNA 作为癌基因或肿瘤抑制因子发挥作用,通过塑造癌症表观基因组来驱动肿瘤进展。lncRNA 通过与表观遗传密码的写入器、读取器和擦除器相互作用,诱导表观遗传修饰,导致癌细胞增殖、凋亡、上皮-间充质转化、迁移、侵袭、转移、癌症干性和化疗耐药性的改变。本综述分析和讨论了 lncRNA 在癌症发病机制、进展、转移和治疗耐药性等方面的多方面作用。它还探讨了通过创新的诊断、预后和治疗策略靶向 lncRNA 的治疗潜力。理解 lncRNA 和表观基因组之间的动态相互作用对于开发个性化治疗策略至关重要,为精准癌症医学提供了新的途径。